Pharmacodynamic Effects of Ranolazine Versus Amlodipine on Platelet Reactivity

• Status: Unknown status
• Trial end date: 2014-06-01
• Target enrollment: 0
• Participant gender: All

Summary

No previous study has assessed the potential of ranolazine to interfere with levels of platelet reactivity in patients with coronary artery disease who are treated with dual antiplatelet therapy.

Aim of this study is to compare the pharmacodynamic effects of maintenance doses of ranolazine versus amlodipine on platelet reactivity in patients with coronary artery disease who are treated with dual antiplatelet therapy.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Roma La Sapienza
• Treatments: Amlodipine; Ranolazine

Criteria

Inclusion Criteria:

• Angiographically-proven coronary artery disease

• Class I indication to dual antiplatelet therapy because of recent (<12 months) percutaneous coronary intervention and/or recent acute coronary syndrome (<12 months)

• Stable clinical conditions

• Able to understand and willing to sign the informed consent form

Exclusion Criteria:

• Use of other drug interfering with CYP activity such as proton pump inhibitors

• Women of child bearing potential patients must demonstrate a negative pregnancy test performed within 24 hours before